Trial Profile

A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Subjects With Metastatic Prostate Cancer

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 07 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Abiraterone acetate/niraparib (Primary) ; Abiraterone acetate; Niraparib; Prednisone
Indications Prostate cancer
Focus Biomarker; Therapeutic Use
Acronyms MAGNITUDE
Sponsors Janssen Research & Development; Janssen-Cilag

01 Apr 2026 Final exploratory results assessing subgroup of patients with Breast Cancer gene-positive (BRCA+) mCRPC enrolled in Asia, published in the International Journal of Urology.
02 May 2025 Planned End Date changed from 19 Feb 2027 to 27 Feb 2027.
02 Apr 2025 Planned End Date changed from 19 Mar 2027 to 19 Feb 2027.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com